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1. Introduction 
The relationship between breast cancer and scleroderma is complex, involving aspects of 
epidemiological coexistence, pathophysiology and treatment. Increased risk of malignancy 
is known to occur in scleroderma patients particularly lung and breast cancer. Risk factors 
for breast cancer in scleroderma patients include older age and autoimmunity status (lack of 
ANA positivity). The sometimes close temporal relationship between breast cancer and 
scleroderma suggests the possible existence of a common pathophysiological mechanism. 
TGF- β and Caveolin-1 have been widely investigated, while researchers also examined 
estrogen receptors, common genetic background and other possible mechanisms. 
Treatment for breast cancer with radiotherapy and taxanes can both induce scleroderma, 
morphea and sclerodermic skin lesions. The existence of scleroderma can affect breast 
cancer treatment and reversely. Breast conservation surgery is avoided in scleroderma 
patients and radiotherapy is also traditionally considered a relative contradiction due to 
more frequent and severe toxicity. 
2. Epidemiology 
There is an increased risk of malignancy in scleroderma patients with an incidence between 
4 and 11% 1,2,3,4,5,6,7. The exact characteristics of this relationship are difficult to assess due to 
the rarity of scleroderma and the consequent lack of statistical power to determine the 
importance of any comparison, the differences in methodology of the studies and the lack of 
knowledge of the detailed pathophysiology of scleroderma. 
Several well-designed population studies have reported a correlation between 
scleroderma and different types of cancers. The results are summarized in Table 1. The 
majority of the studies reported a significantly elevated SIR of between 1-5 and 3.15 1 2 3 4 8 
5. In contrast, Chatterjee et al 9 found no statistically significant increase in malignancy in 
patients with scleroderma compared with the normal population. The only malignancy 
with a significantly increased risk was liver cancer in black females. The commonest 
cancer type occurring in scleroderma is lung cancer, while data over other cancer types 
are not clear1. 
In terms of breast cancer risk, some studies such as those of Siau et al 2 and Abu – Shakra et 
al 4 found a statistically important correlation with SIRs 3,07 and 6,1 respectively, while 
others 3,8 reported a non statistically significant correlation or no correlation at all.1, 5, 9  
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Author SIR 95% CI 
Olesen 1.5 1.3-1.7 
Siau 3.15 1.77-5.2 
Hill 1.99 1.46-2.65 
Abu-Shakra 2.1  
Derk 1.55 1.16-1.93 
Rosenthal 2.4 1.5-3.6 
Chatterjee 1.23  
Table 1. Scleroderma and Standardised Incidence Rate of malignancy. 
The risk factors for malignancy in patients with scleroderma , in particular breast cancer are 
not determined. Siau et al 2 found age > 70 to be an important risk factor, while Abu – 
Shakra et al 4 found an increased risk for age > 65 for all cancer types. Derk et al reported that 
the diagnosis of scleroderma occurs in older patients with cancer in general 8 or breast 
cancer10, while Lu et al 11 concluded that age of scleroderma diagnosis was irrelevant to age 
of breast cancer diagnosis. Kyndt 7 reported that scleroderma patients with breast cancer 
had their scleroderma diagnosis at a later age than patients with scleroderma only, but this 
difference was not statistically significant. 
The role of the gender of the patients is not determined either. Most authors state that both 
male and female scleroderma patients are at higher risk of developing cancer in comparison 
to the general population, but there is no agreement as to whether the correlation is stronger 
for men 1,3,4,8 or women5. It is important to highlight that both breast cancer and scleroderma 
predominately affect women. 
As for the scleroderma type, data are also equivocal. Some authors 9,11 believe that 
scleroderma type is not important while some others 4,7 find various differences that do not 
reach statistical importance. Siau et al 2 report that limited scleroderma is a risk factor for 
cancer development and Hill et al 3 states the same for diffuse scleroderma. Systemic 
sclerosis, morphea and breast cancer can coexist12. 
With regard to the autoimmune status of the patients, most authors 3,4,9,7 agree that ANA, Scl 
70 and U1 - RNP antibody status do not constitute a risk factor for cancer development. 
Reports focusing on breast cancer however10, 11 find the lack of ANA positivity to be a risk 
factor for breast cancer development. Family history is considered a risk factor for all cancer 
types in scleroderma patients 8 and also for breast cancer. On the other hand, scleroderma 
patients with breast cancer use Hormone Replacement Therapy less frequently than those 
without the disease but this finding may be biased11, 10. 
Breast cancer diagnosis can precede, follow or coincide with diagnosis of scleroderma. To 
evaluate this relationship, it has to be taken in consideration that authors use different 
definitions of “simultaneous”, accepting a time lag from 1 to 6 months between the breast 
cancer and scleroderma diagnosis. Derk 10 studied two groups, one with breast cancer and 
scleroderma and another with scleroderma only (control group). The first group was the 
divided into two subgroups: those in whom breast cancer diagnosis followed the 
scleroderma diagnosis (48%) and those in which it preceded (52%). When these groups were 
www.intechopen.com
 
Scleroderma and Breast Cancer 543 
compared for age at scleroderma diagnosis it emerged that patients with breast cancer 
diagnosis prior to scleroderma diagnosis were older than the ones with breast cancer after 
scleroderma. This difference was however not statistically significant. In contrast, for the 
group in which breast cancer was diagnosed prior to scleroderma with the control group, 
the difference reached statistical significance. This was not true for the group in which 
breast cancer diagnosis followed scleroderma diagnosis. The first subgroup of patients was 
ANA negative compared with patients with scleroderma only, and this attained statistical 
significance when the second subgroup were compared with the control subgroup. Not all 
researchers agree on the timing of diagnoses of the two conditions. In another study by Lu et 
al 11 cancer diagnosis predated scleroderma diagnosis in only 24% of the patients and 
followed in 76%. 
Others13,14 have underlined the close temporal relationship between scleroderma diagnosis 
and breast cancer diagnosis, and explored the possibility of a pathophysiological connection 
between them. Pineda et al 15 described a rare case of bilateral breast carcinoma and diffuse 
scleroderma. Possible aetiologies for this include scleroderma as a true paraneoplasmatic 
syndrome, a common background immunological abnormality, or a detection bias due to 
extensive investigation of unwell patients.16 
3. Pathophysiology 
While the epidemiological connection between cancer and scleroderma is well established, 
any pathophysiological relationship is not clear yet. Certain mechanisms such as lung 
fibrosis have been incriminated for lung cancer, the commonest coexisting cancer in 
scleroderma patients, but few data exist for other cancer types. 
Epidemiological correlations do not necessarily mean aetiological correlation, since they can 
be attributed to higher prevalence of both diseases in older ages17, female gender18 or a 
diagnostic bias from close follow-up and extensive clinical investigation. Yet, there is some 
evidence that could support the existence of mechanisms that, in some extent, connect the 
two diseases. Hypotheses for these include a common genetic background, a common 
mechanism or finally scleroderma as a consequence of breast cancer radiotherapy and 
chemotherapy. 
With regard to the common genetic background, scleroderma patients have been 
occasionally reported to have a breast cancer family history11. Genetic polymorphism has 
been incriminated and HLA-DR2 haplotype is more frequent in scleroderma and breast 
cancer patients.17 Explanations proposed include that this haplotype confers to a germline 
BRCA mutation or is at a genetic linkage to it.11 
Mechanisms involving both conditions include TGF-β/Smad signaling pathway that is 
known to regulate many events in scleroderma, especially in the pathogenesis of fibrosis via 
upregulation of collagen expression 19. On the other hand, increased collagen formation, 
expressed as greater mammographic density20 is a recognized risk factor for breast cancer 
development. Interestingly TGF β is a known breast tumor suppressor21 although certain 
reports refer both to proliferative and suppressive action22. TGF-β levels are increased in 
breast cancer patients and, in those having limited disease, they decrease after resection of 
the tumor23 
Another piece of evidence that could potentially indicate common pathophysiology is the 
breast tumor associated antigen Ca 15-3 (MUC-1) which is increased in scleroderma 
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patients, and correlates with more severe disease including renal and joint involvement, 
ANA positivity and elevated CRP24. Furthermore, scleroderma has sometimes evolved in 
women undergoing breast augmentation surgery and the proposed mechanism was 
fibroblastic actions of silica or a Graft versus Host disease25 
Sex hormone changes are also involved in the pathophysiology of both diseases. Certain 
predisposing factors for breast cancer such as nulliparity 26 or protective factors like 
increasing number of births 27 alter the course of scleroderma disease. Existence of parity 
delays scleroderma onset and decreases disease mortality and morbidity but does not alter 
duration26. Not only estrogens but also genetic alterations in estrogen receptors (ER) are 
involved in the pathogenesis of scleroderma. Specifically ERa XbaI GG phenotype was 
significantly less frequent in systemic scleroderma patients than in healthy controls 
although no association with clinical manifestations was found28. Nevertheless, ERa up-
regulation is an early event during mammary hyperplasia and adenocarcinoma 
development.29 
The two conditions are also connected in studies focusing on certain mediators such as 
Caveolin I, a regulator that inhibits the baseline activity of several pro-proliferative and 
oncogenic proteins via the TGF-β/Smad signaling pathway30. Caveolin-1 is known to 
suppress collagen expression via interactions with TGF - β31 and also has a variety of effects 
on breast cancer development such as up-regulation of ERa or molecular changes necessary 
in the development of metastasis as confirmed in mouse models. Caveolin-1 normally 
inhibits metastases via suppression of matrix metalloproteinase secretion that degrades the 
basement membrane of normal epithelia 32,33. In humans loss of stromal caveolin-1 is a novel 
breast cancer biomarker that predicts early disease recurrence, metastasis, survival, and 
tamoxifen resistance.34  
Post irradiation morphea was first described in 1905, the first large series in 198935. 
Radiotherapy for breast cancer can induce scleroderma through various mechanisms. After 
radiotherapy morphea in the breast region is a relatively common manifestation, but 
systemic scleroderma has also been occasionally reported.36 Its frequency is calculated at up 
to 1/500 37,38. The hypothesis of a systemic mechanism, triggered by radiotherapy is 
supported by the scleroderma appearance away from the radiated field. Possible 
mechanisms involve T cell activation 36 and clonal fibroblast population alteration. Selective 
local immune alteration, including TGF-β increase and endothelial alterations have also 
been proposed for radiation caused scleroderma39, 37. 
Research on predictive factors for breast cancer patients to develop scleroderma 
manifestations is inconclusive. Patient age, total dose of radiation, dose per fraction, severity 
of the acute reaction and tamoxifen use do not appear significant.37 Several studies however 
indicate the severity of scleroderma is an important predictive factor40. Finally apart from 
radiotherapy, chemotherapy especially with docetaxel and paclitaxel has been reported to 
occasionally induce scleroderma41,42,43,44. 
4. Treatment 
A possible relation between the two diseases could potentially lead to treatment 
alternations with dilemmas occurring mainly when scleroderma patients develop a breast 
cancer. No evidence exists in the literature that the core treatment – surgery – should be 
altered but questions over adjuvant chemotherapy and radiotherapy have been raised. 
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Finally, hormonal and biological therapies do not seem to interfere with the course of 
scleroderma. 
Scleroderma is a relative contradiction for radiotherapy due to possible sensitivity of the 
tissue affected by the disease. Many doctors hesitate to treat breast cancer in scleroderma 
patients with breast conservation45,46, although large studies failed to prove severe 
toxicity48,49, such as grade III or IV toxicity (severe adverse events or life threatening or 
disabling adverse events respectively). It has been stated that clinicians consider 
radiotherapy to be contraindicated to scleroderma patients because mainly of publication 
bias, severe cases of toxicity being written up as case reports, while cases with mild 
toxicity or no toxicity are omitted 38.  
A large study by Lin et al50 found no differences in early toxicity, but differences were 
found in late toxicity. Proven prognostic factors for scleroderma patients developing 
toxicity effects are curative treatment, multi organ involvement of scleroderma for acute 
toxicity and negative antinuclear antibodies for late toxicity.51. However these results 
reach statistical importance for mild toxicity only (Grade 1 and 2 according to Common 
Terminology Criteria for Adverse Events version 3.0 grading scales). 
Another implication of the coexistence of scleroderma and breast cancer is imaging 
surveillance after breast conservation. This may be difficult due to breast fibrosis and is 
sometimes achieved only by MRI.47  
On the other hand, previously healthy patients who receive radiotherapy for breast cancer 
can develop sclerodermatic changes. The typical clinical picture includes sclerotic and 
pigmentary lesions in the breast, initially severe and painful but self – limited. 37 The 
initial calculation of its incidence at 0.2% is probably an overestimate. This situation is 
rare and is only reported in sparse case reports in the English literature35,38,39. 
In these cases the clinician can use the appropriate scleroderma therapy and topical 
steroids, calcineurin inhibitors or low doses of systemic immunosuppressants (steroids, 
methotrexate MTX cyclosporine) can be applied. Topical softening of the tissue can be 
achieved by means of heparin, hyaluronidase, UVA1 irradiation, PUVA irradiation, or the 
systemic administration of penicillamine with various success 54,52,55. 
5. Conclusions 
While the relationship between cancer and scleroderma is strongly suggested, its 
characteristics are not yet clarified and more research is required. Questions to be answered 
include underlying pathophysiological mechanisms and alterations in the treatment for 
scleroderma patients. Coexistence of scleroderma and breast cancer can be a challenging 
problem, involving general surgeons, rheumatologists, oncologists, radiologists and, last but 
not least, mental health professionals since the coexistence of two diseases can affect the 
patients’ psychological status and their compliance with the treatment. A multidisciplinary 
approach with doctors, nurses and paramedics, high clinical vigilance and cooperation is 
required so to avoid undesirable consequences. 
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